Showing results (101-110 of 112) with videos related to
Sort By:
Pageof 12
European Journal of Nuclear Medicine and Molecular Imaging|March 24, 2022
Feasibility of [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinomaLena M Unterrainer, Simon Lindner, Lennert Eismann, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 25, 2025
Potential value of [<sup>68</sup>Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: a bi-centric analysisKim M Pabst, Sophie C Siegmund, Adrien Holzgreve, et al.European Journal of Nuclear Medicine and Molecular Imaging|June 26, 2023
Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [<sup>18</sup>F]SiTATEMarcus Unterrainer, Sophie C Kunte, Lena M Unterrainer, et al.Theranostics|June 16, 2025
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapyFelix L Herr, Christian Dascalescu, Ricarda Ebner, et al.Biomedicines|May 28, 2022
Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&TLena M Unterrainer, Leonie Beyer, Mathias J Zacherl, et al.Biomedicines|January 23, 2024
The Traumatic Inoculation Process Affects TSPO Radioligand Uptake in Experimental Orthotopic GlioblastomaLukas Gold, Enio Barci, Matthias Brendel, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 3, 2023
Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type GlioblastomaNathalie L Albert, Debie V Nelwan, Daniel F Fleischmann, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 24, 2025
Evidence-Based Clinical Protocols to Monitor Efficacy of [<sup>177</sup>Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World DataLena M Unterrainer, Nicolas De Leiris, Marcus Unterrainer, et al.European Urology Oncology|August 21, 2023
Real-world Outcomes and Predictive Biomarkers for <sup>177</sup>Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational StudyMona Kafka, Andreas Horninger, Gianpaolo di Santo, et al.Frontiers in Oncology|February 16, 2023
Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [<sup>18</sup>F]SiTATERalf S Eschbach, Markus Hofmann, Lukas Späth, et al.Pageof 12